Paper Details
- Home
- Paper Details
Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition.
Author: BinnsJacquelyn, BowlbyMark R, BrunnerJoseph, CannonChristopher E, ColemanPaul J, EddinsDonnie M, FoxSteven V, GarsonSusan L, GotterAnthony L, HodgsonRobert, KudukScott D, McdonaldTerrence P, RengerJohn J, SavitzAlan T, StevensJoanne, TannenbaumPamela L, TyeSpencer J, UslanerJason M, WangXiaohai, WinrowChristopher J, YaoLihang
Original Abstract of the Article :
Current treatments for insomnia, such as zolpidem (Ambien) and eszopiclone (Lunesta), are γ-aminobutyric acid type A (GABAA)-positive allosteric modulators that carry a number of side effects including the potential to disrupt cognition. In an effort to develop better tolerated medicines, we have id...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1126/scitranslmed.3005213
データ提供：米国国立医学図書館（NLM）
Orexin Receptor Antagonists: A New Dawn in Insomnia Treatment
Insomnia, like a relentless sandstorm that disrupts sleep, can have a profound impact on a person's well-being. This research, like a group of researchers seeking a more effective and safer treatment for insomnia, explores the potential of dual orexin 1 and 2 receptor antagonists (DORAs) as a novel class of sleep-promoting drugs. The authors compare the effects of DORAs to those of standard sleep drugs like zolpidem and eszopiclone, which are known to have cognitive side effects.
DORAs: A More Targeted Approach to Insomnia Treatment
The study found that DORAs, like a carefully crafted oasis in the desert of insomnia, promote sleep at doses that do not significantly disrupt cognition. The researchers observed that DORAs have a wider therapeutic margin for sleep versus cognitive impairment compared to standard sleep drugs. This finding suggests that DORAs may offer a more targeted approach to treating insomnia, addressing sleep disturbances without compromising cognitive function. This discovery is a significant step forward in developing safer and more effective treatment options for insomnia, potentially offering a more comfortable and productive path for those struggling with sleep.
Navigating the Desert of Sleep Disturbances
This research highlights the potential of DORAs as a promising new class of sleep-promoting drugs. The findings underscore the importance of developing targeted treatments that address sleep disturbances without compromising cognitive function. This research offers a ray of hope in the desert of insomnia, paving the way for a more restful and productive sleep experience for those struggling with this common condition.
Dr. Camel's Conclusion
This study explores the potential of DORAs as a new and promising treatment for insomnia, offering a more targeted and less disruptive approach to sleep enhancement. It underscores the importance of developing medications that address sleep disturbances without compromising cognitive function, leading to a more comfortable and productive life for those struggling with insomnia.
Date :
- Date Completed 2013-09-30
- Date Revised 2022-04-08
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.